Recent

% | $
Quotes you view appear here for quick access.

OCATA THERAPEUTICS, INC. Message Board

  • blackmarango blackmarango Aug 16, 2014 11:17 AM Flag

    Regeneron - Eylea

    I was just looking at some articles on CNN - Money and came across a video of a doctor injecting older citizens with a drug, Eylea, to help with vision disorders. The company's name is Regeneron. Medicade/ Medicare are paying for it.

    As I've opined before, it's way past time to release the Phase I results and get on with the subsequent testing. Let's get the word out to the Market Investors, the Medical Community, and the General Public!!! "We don't need no stink'n NEJM!"

    If Regeneron got a video clip on CNN - Money, I'd strongly suggest that Dr. Wotton try to do the same.

    Time is DEFINITELY wasting.

    Time to start the progress ball rolling!!!

    Of course, IMO.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Regeneron and their outrageous market cap will be ours in 5 years & they will have ACTC mkt cap.

    • Get lost IDIOT...

      Sentiment: Strong Buy

    • Folks: I'll strongly suggest to all of you that one of the first things that Dr. Wotton does is get the results released by whatever means available and, then, get on with the human testing.

      There has been too much silence for too long.

      What's it been, last summer since we've had testing news?

      And, what about the rumors of good news over in the UK?

    • Re: As I've opined before, it's way past time to release the Phase I results and get on with the subsequent testing. Let's get the word out to the Market Investors, the Medical Community, and the General Public!!! "We don't need no stink'n NEJM!"

      You are just wrong about this, blackmarango. It is absolutely necessary to have these results come out in a prestigious journal with peer-reviewed articles. There is no other way to getting the impact that will have.

      I feel confident that what you call wasted time is actually time being well spent to make the data as clear and definitive as possible in the service of demonstrating the full potential of the treatment. Given the incredible technology now available to look into the eye ACT knows very well that if they get this done right it will be explosive.

      Sentiment: Strong Buy

      • 2 Replies to elk_1l
      • "We don't need no stink'n NEJM!"

        Yes elky, ya do need a no "stink'n NEJM" The NEJM is a VERY reputable publication that dispenses valid and undisputable breakthrough/research information to the medical/science community. Before ya get published in NEJM or the Lancet, ya research results and data has to meet very stringent qualifications and in most cases reproducible. They are a VERY REPUTABLE organization, who will not be bullied or coerced to cater to any entity.

        I am sure ya don't want an incident like the Japanese Stem-Cell Scientist Yoshiki Sasai, who commited suicide for cooking the books and the data that was published in the journal "Nature". And we know what happened with "Nature". The NEJM will, under NO circumstance be tainted by anyone or entity.

        Submitting claims of reversing "blindness" with stem cell doesn't mean it is so....not discounting ACTC claims, but the data has to be vetted and it takes time. If the ACTC data is valid, then it would be worth the wait. Ya know everything is measured, especially when R/S is looming and uplisting is in the plan. Maximum mileage is the life blood of research data release, especially for a junior pharma and any potential suitor.

      • elk: well, then, we'll just have to agree to disagree.

        These results were supposedly given to be published last December. It's been about 8 months and no publication.

        So, how long are you willing to wait? As long as it takes???

        Either the NEJM or whatever should publish the results or inform ACTC that they will not. If they do neither, then ACTC MUST RELEASE the results and get on with their testing.

        A good video clip on CNN - Money may be worth more than a peer reviewed journal article. Especially if it was followed up with more good news!!!

        Time is wasting!!!

        Of course, IMO.

    • "IMO"
      And just what is that worth???

 
ACTC
0.00(0.00%)